Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo. (23rd May 2021)

• Record Type: Journal Article
• Authors: Zhou, Dongrui; Cen, Kai; Liu, Wei; Liu, Fengzhi; Liu, Ruijia; Sun, Yikun; Zhao, Yizhou; Chang, Jingling; Zhu, Lingqun
• Is Part Of: Journal of ethnopharmacology. Volume 272(2021)
• Publication Date: 2021-05-23
• Subjects: Xuesaitong -- Panax notoginseng saponins -- Stroke -- Nogo-A -- ROCKⅡ -- Y27632; XST Xuesaitong -- PNS Panax notoginseng saponins -- Nogo-A Neurite outgrowth inhibitor-A -- MCAO Middle cerebral artery occlusion -- OGD/R Oxygen-glucose deprivation/reperfusion -- TTC Triphenyl tetrazolium chloride -- NDS Neurological deficit score -- HE Hematoxylin-eosin -- IHC Immunohistochemical -- SYN Synaptophysin -- PSD-95 Postsynaptic density protein-95 -- qRT-PCR quantitative real-time polymerase chain reaction -- CCK8 Cell counting kit 8 -- CNS Central nervous system -- ECA External carotid artery -- ICA Internal carotid artery -- IOD Integrated optical density; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2021.113943
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Xuesaitong (XST) is a traditional Chinese medicine injection with neuroprotective properties and has been extensively used to treat stroke for many years. The main component of XST is Panax notoginseng saponins (PNS), which is the main extract of the Chinese herbal medicine Panax notoginseng . Aim of the study: In this study, we investigated whether XST provided long-term neuroprotection by inhibiting neurite outgrowth inhibitor-A (Nogo-A) and the ROCKII pathway in experimental rats after middle cerebral artery occlusion (MCAO) and in SH-SY5Y cells exposed to oxygen-glucose deprivation/reperfusion (OGD/R). Materials and methods: Rats with permanent MCAO were administered XST, Y27632, XST plus Y27632, and nimodipine for 14 and 28 days. Successful MCAO onset was confirmed by 2, 3, 5-triphenyl tetrazolium chloride (TTC) staining. Neurological deficit score (NDS) was used to assess neurological impairment. Hematoxylin-eosin (HE) staining and immunohistochemical (IHC) analysis of synaptophysin (SYN) and postsynaptic density protein-95 (PSD-95) were performed to evaluate cerebral ischemic injury and the neuroprotective capability of XST. Nogo-A levels and the ROCKII pathway were detected by IHC analysis, western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR) to explore the protective mechanism of XST. OGD/R model was established in SH-SY5Y cells. Cell counting kit 8 (CCK8) was applied to detect the optimum OGD time and XST concentration. The expression levels Nogo-A and ROCKII pathway were determined using western blotting. Results: Our results showed that XST reduced neurological dysfunction and pathological damage, promoted weight gain and synaptic regeneration, reduced Nogo-A mRNA and protein levels, and inhibited the ROCKII pathway in MCAO rats. CCK8 assay displayed that the optimal OGD time and optimal XST concentration were 7 h and 20 μg/mL respectively in SH-SY5Y cells. XST could evidently inhibit OGD/R-induced Nogo-A protein expression and ROCKII pathway activation in SH-SY5Y cells. Conclusions: The present study suggested that XST exerted long-term neuroprotective effects that assisted in stroke recovery, possibly through inhibition of the ROCKII pathway. Graphical abstract: Image 1